Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics' subcutaneously administered version of VK2735 has generated competitive data in the phase 2 trial in obese patients. The oral formulation of VK2735 reported good tolerability that leaves room for exploration of higher doses. VK2735 makes Viking an attractive buyout candidate or big pharma partner.

What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner

Celsius Holdings

Super Micro Computer

Investing in Russell 2000 stocks is a smart idea because it focuses on small-cap stocks with substantial growth potential. While individual stocks within the index vary, some are poised to offer significant gains.

The 3 Best Russell 2000 Stocks to Buy in May 2024

Altimmune

Amgen

AstraZeneca

Structure Therapeutics Inc

Merck

Pfizer

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

Viking Therapeutics, a clinical-stage company focused on metabolic and endocrine disorders, is primed for acquisition due to its robust pipeline and potential as a market disruptor.

Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired

AbbVie

Cytokinetics

Eli Lilly

Novo Nordisk

Roivant Sciences Ltd

Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

Life Time Group Holdings

Xponential Fitness

According to Harvard University, about two-thirds of United States adults are “overweight or obese,” while 36% are obese. And the university predicts that, at the current rate, about 50% of Americans will be obese by 2030.

What Is the Best Weight Loss Stock to Buy Now? Our Top 3 Picks

CRISPR Therapeutics

While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of recessions that Western economies experienced over the last 40 years or so.

Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge

Viking Therapeutics posted a narrower-than-expected loss in the first quarter. The company looks to be making significant strides in clinical trials.

Viking Therapeutics Delivers Smaller-Than-Expected Q1 Loss

Viking Therapeutics has been one of the few standouts in healthcare this year. The company's experimental weight loss candidate has fueled a sharp uptick in its share price over the prior 13 months.

Is Viking Therapeutics Incredibly Undervalued?

Viking Therapeutics is developing two highly promising medicines. If the company succeeds, its share price will skyrocket even more.

Can This High-Flying Stock 10x in 10 Years?

Biohaven Pharmaceutical Hld

If you follow Warren Buffett's advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlying necessity of the ecosystem.

3 Biotech Stocks to Buy on the Dip: April 2024

Iovance Biotherapeutics

Recursion Pharmaceuticals

Oncology's future prominently features the kind of autoimmune R&D work that Iovance is doing. Helped by new technology, Recursion is using artificial intelligence to develop new drugs.

3 Millionaire-Maker Biotech Stocks

Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcript

Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From Baseline) at 13 Weeks; Shown to be Safe and Well-Tolerated Results From Phase 1 Trial of Oral VK2735 Demonstrated Promising Safety and Tolerability With Up to 3.3% Placebo-Adjusted Weight Loss (5.3% From Baseline) at 28 Days 52-Week Histology Results From Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Expected in 2Q24 Completed Public Offering of Common Stock Raising Gross Proceeds of Approximately $630 Million ; Quarter-End Cash Position of $963 Million SAN DIEGO , April 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intra-Cellular Therapies

Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.

3 Biotech Stocks With Skyrocketing Potential: April 2024

Geron

Neurocrine Biosciences

The economy is currently on a stable trajectory and is poised for sustained growth; the indicators show a positive outlook overall. However, the biotech industry presents even more compelling potential, demonstrating a compounding annual growth rate (CAGR) of 13.96% from 2024 to 2030.

3 Red-Hot Biotech Rockets Blasting Off in 2024

Vertex Pharmaceuticals

Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy. Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this comparison, Pfizer scans as a safer choice for cautious investors, while Viking Therapeutics may appeal to risk-tolerant growth investors.

Better Buy: Pfizer vs. Viking Therapeutics

Salesforce

Shopify

Many investors look to analysts' expectations to guide their movements each quarter. Typically, those investors can reasonably use estimates as a reference.

3 Stocks With the Potential to Surpass Analyst Expectations for 2024

GoodRx Holdings

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Sana Biotechnology

Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization.

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.

Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights

VKTX has reported positive data from a phase 1 trial of the oral formulation of VK2735, showing a placebo-adjusted weight loss of 3.3% at the highest dose at 28 days. There was an absence of plateauing of weight loss at 4 weeks at the higher doses, meaning longer treatment could yield further weight loss. Viking plans to continue dose escalation in the current trial meaning further data might not be far ahead, especially if VKTX doses patients for just 4 weeks.

Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead

Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time SAN DIEGO , April 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.

News for Viking Therapeutics Stock (VKTX)